EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

First Report of Real World Utilization of an Activin Signaling Inhibitor in Patients With Severe Pulmonary Arterial Hypertension in the Middle East PH RISE‐ME Study

Mutia Al Jabi iD, Hani Sabbour iD, Lama Mohamed, Sarah Alsultan iD, Maryam Almassabi iD, Moaz Osama, Amal Abudouleh iD, Malak Sondoqah iD, Mohamed Khalid Zaki, Ahmed Hesham iD, Khaled M Saleh, Mawhid U I Haque iD und 1 weitere

Pulmonary Circulation · 2026-10 · 16 (4)

DOI: 10.1002/pul2.70434 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pulmonary Circulation, online erschienen am 22.10.2026. Verfasst von Mutia Al Jabi und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Academics and Medical Education Mediclinic Airport Road Hospital Abu Dhabi United Arab Emirates. Die Arbeit nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pulmonary arterial hypertension (PAH) remains associated with substantial morbidity and mortality despite advances in combination therapy. Sotatercept, an activin‐signaling inhibitor, is a novel disease‐modifying therapy targeting pulmonary vascular remodeling. Real‐world data from Middle Eastern populations remain limited. We conducted a retrospective single‐center cohort study evaluating the real‐world effectiveness and safety of Sotatercept in adults with PAH treated at a tertiary pulmonary hypertension expert center in Abu Dhabi, United Arab Emirates, between January 2025 and September 2026. Clinical, echocardiographic, biochemical, and risk‐stratification data were extracted from electronic medical records. Primary outcomes were echocardiographic parameters of pulmonary hemodynamics and right ventricular structure and function, including right atrial (RA) area, systolic pulmonary arterial pressure (SPAP), TAPSE, and TAPSE/SPAP ratio. Secondary outcomes included NT‐proBNP, 6‐min walk distance (6MWD), risk profile, and safety. Thirty‐six patients were prescribed Sotatercept, of whom 33 received at least one dose. Most patients were female (80.6%), with a mean age of 55 years. Significant reductions occurred in RA area (− 2.67 cm 2 ; 95% CI, −4.16 to −1.18; p < 0.001), NT‐proBNP (− 46.7 pmol/L; 95% CI, −87.19 to −20.39; p < 0.001), and SPAP (− 6.00 mmHg; 95% CI, −12.00 to −0.50; p = 0.031). TAPSE increased significantly (+ 0.25 cm; 95% CI, 0.17 to 0.33; p < 0.001), and TAPSE/SPAP improved significantly (+ 0.064; 95% CI, 0.030 to 0.108; p < 0.001). Risk profile improved, with 12 patients (36.4%) at low risk at follow‐up; two patients (6.1%) remained at high risk. The 6MWD did not change significantly. Treatment was well tolerated, with no adverse events leading to treatment discontinuation or death; two all‐cause deaths occurred during follow‐up. In this real‐world Middle Eastern PAH cohort, Sotatercept was associated with improved right‐heart remodeling, NT‐proBNP, and risk profile, with acceptable short‐term safety. These findings complement trial evidence and provide early regional support for activin pathway inhibition in routine practice.

Schlagwörter

Stichwörter der Autor:innen

cardiologycohortcohort studycombination therapyinternal medicinemedicinepulmonary hypertension

Autor:innen und Institutionen

  • Department of Academics and Medical Education Mediclinic Airport Road Hospital Abu Dhabi United Arab Emirates.
  • Department of Cardiology Mediclinic Airport Road Hospital Abu Dhabi United Arab Emirates.
  • Respiratory Division, Integrated Hospital Institute Cleveland Clinic Abu Dhabi United Arab Emirates.
  • Basic Medical Sciences, College of Medicine University of Sharjah Sharjah United Arab Emirates.
  • Department of Pulmonary and Critical Care Medicine Lahey Hospital and Medical Center Burlington USA.

ORCID-Profile: Mutia Al Jabi, Hani Sabbour, Sarah Alsultan, Maryam Almassabi, Amal Abudouleh, Malak Sondoqah, Ahmed Hesham, Mawhid U I Haque, Ioana Preston

Zitieren

APA

Jabi, M. A., Sabbour, H., Mohamed, L., Alsultan, S., Almassabi, M., Osama, M., Abudouleh, A., Sondoqah, M., Zaki, M. K., Hesham, A., Saleh, K. M., Haque, M. U. I., & Preston, I. (2026). First Report of Real World Utilization of an Activin Signaling Inhibitor in Patients With Severe Pulmonary Arterial Hypertension in the Middle East PH RISE‐ME Study. Pulmonary Circulation, 16(4). https://doi.org/10.1002/pul2.70434

Vancouver

Jabi MA, Sabbour H, Mohamed L, Alsultan S, Almassabi M, Osama M, et al. First Report of Real World Utilization of an Activin Signaling Inhibitor in Patients With Severe Pulmonary Arterial Hypertension in the Middle East PH RISE‐ME Study. Pulmonary Circulation. 2026;16(4). doi:10.1002/pul2.70434

BibTeX
@article{Jabi2026,
  author = {Jabi, Mutia Al and Sabbour, Hani and Mohamed, Lama and Alsultan, Sarah and Almassabi, Maryam and Osama, Moaz and Abudouleh, Amal and Sondoqah, Malak and Zaki, Mohamed Khalid and Hesham, Ahmed and Saleh, Khaled M and Haque, Mawhid U I and Preston, Ioana},
  title = {First Report of Real World Utilization of an Activin Signaling Inhibitor in Patients With Severe Pulmonary Arterial Hypertension in the Middle East PH RISE‐ME Study},
  journal = {Pulmonary Circulation},
  year = {2026},
  volume = {16},
  number = {4},
  doi = {10.1002/pul2.70434}
}
Kostenlos starten →